Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dermata Therapeutics, Inc. stock logo
DRMA
Dermata Therapeutics
$0.34
-5.6%
$0.40
$0.23
$3.68
$2.27M0.87692,994 shs9,619 shs
Metacrine, Inc. stock logo
MTCR
Metacrine
$0.58
$0.57
$0.30
$0.59
$24.75M-0.73225,834 shs83,889 shs
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$0.08
$0.12
$0.07
$1.42
$2.80M1.973.36 million shs528,287 shs
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
$0.01
$0.01
$0.01
$0.02
N/AN/AN/AN/A
NVLNF
Novelion Therapeutics
$0.70
-1.2%
$0.70
$0.51
$1.00
$13.77M2.15261,364 shs26,900 shs
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dermata Therapeutics, Inc. stock logo
DRMA
Dermata Therapeutics
+5.03%+20.99%-14.07%-22.77%-82.07%
Metacrine, Inc. stock logo
MTCR
Metacrine
0.00%0.00%0.00%0.00%+3.82%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
+1.71%-4.80%-40.03%-49.14%+7,729,900.00%
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
0.00%0.00%0.00%-50.00%0.00%
NVLNF
Novelion Therapeutics
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Dermata Therapeutics, Inc. stock logo
DRMA
Dermata Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Metacrine, Inc. stock logo
MTCR
Metacrine
N/AN/AN/AN/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/AN/AN/AN/AN/AN/AN/AN/A
NVLNF
Novelion Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dermata Therapeutics, Inc. stock logo
DRMA
Dermata Therapeutics
N/AN/AN/AN/A
Metacrine, Inc. stock logo
MTCR
Metacrine
N/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/AN/AN/AN/A
NVLNF
Novelion Therapeutics
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dermata Therapeutics, Inc. stock logo
DRMA
Dermata Therapeutics
N/AN/AN/AN/A$1.62 per shareN/A
Metacrine, Inc. stock logo
MTCR
Metacrine
N/AN/AN/AN/A$1.36 per shareN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$14.73M0.19N/AN/A$0.12 per share0.65
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/AN/AN/AN/A$0.04 per shareN/A
NVLNF
Novelion Therapeutics
$130.43M0.11N/AN/A($4.69) per share-0.15

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dermata Therapeutics, Inc. stock logo
DRMA
Dermata Therapeutics
-$7.80M-$3.65N/AN/AN/A-107.95%-93.59%5/9/2024 (Estimated)
Metacrine, Inc. stock logo
MTCR
Metacrine
-$62.21M-$1.03N/AN/AN/A-84.88%-59.33%N/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
-$9.64M-$3.82N/A1.11N/A-65.46%-150.14%-53.48%N/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
-$8.45MN/A0.00N/AN/A-63.75%-57.93%N/A
NVLNF
Novelion Therapeutics
-$108.33MN/A0.00N/AN/AN/AN/AN/A

Latest NBY, DRMA, NEVPF, MTCR, and NVLNF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/26/2024Q4 2023
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/A-$0.95-$0.95-$0.57N/A$3.73 million    
3/21/2024Q4 2023
Dermata Therapeutics, Inc. stock logo
DRMA
Dermata Therapeutics
N/A-$0.21-$0.21-$0.21N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dermata Therapeutics, Inc. stock logo
DRMA
Dermata Therapeutics
N/AN/AN/AN/AN/A
Metacrine, Inc. stock logo
MTCR
Metacrine
N/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/AN/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/AN/AN/AN/AN/A
NVLNF
Novelion Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dermata Therapeutics, Inc. stock logo
DRMA
Dermata Therapeutics
N/A
4.91
4.91
Metacrine, Inc. stock logo
MTCR
Metacrine
0.34
12.15
12.15
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/A
1.67
1.00
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/A
6.60
6.60
NVLNF
Novelion Therapeutics
N/AN/AN/A

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Dermata Therapeutics, Inc. stock logo
DRMA
Dermata Therapeutics
86.66 million6.04 millionNot Optionable
Metacrine, Inc. stock logo
MTCR
Metacrine
1042.57 million36.70 millionNot Optionable
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
2436.06 million35.59 millionNot Optionable
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
8N/AN/ANot Optionable
NVLNF
Novelion Therapeutics
10919.62 millionN/ANot Optionable

NBY, DRMA, NEVPF, MTCR, and NVLNF Headlines

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Dermata Therapeutics logo

Dermata Therapeutics

NASDAQ:DRMA
Dermata Therapeutics, Inc., a clinical-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Metacrine logo

Metacrine

NASDAQ:MTCR
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
NovaBay Pharmaceuticals logo

NovaBay Pharmaceuticals

NYSE:NBY
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Abliva AB (publ) logo

Abliva AB (publ)

OTCMKTS:NEVPF
Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

Novelion Therapeutics

OTCMKTS:NVLNF
Novelion Therapeutics Inc., a biopharmaceutical company, develops therapies for individuals living with rare diseases in the United States, Japan, Brazil, and internationally. Its commercial products include metreleptin, a recombinant analog of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPTA brand name; and lomitapide capsule for the treatment of adult patients with homozygous familial hypercholesterolemia under the JUXTAPID and LOJUXTA brands. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.